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Summary
Background: Sick sinus syndrome (SSS) is often complicated with the additional presence of
atrial ﬁbrillation (AF). Atrial septal pacing, compared with right atrial appendage (RAA) pacing,
shortens the atrial conduction time and reduces the dispersion of the refractoriness. However,
low atrial septal (LAS) pacing’s efﬁcacy for preventing AF in SSS remains controversial in Japan.
Methods and results: We analyzed 95 consecutive patients with SSS who underwent dual-
chamber pacemaker implantations. Forty-two patients (44%) had a history of AF at the time of
the pacemaker implantation. In the group without a history of AF, LAS pacing was performed
in 17 patients, and RAA pacing in 36 patients. In the group with a history of AF, LAS pacing was
performed in 15 patients, and RAA pacing in 27 patients. We evaluated whether LAS pacing
prevented the development of de novo AF and the persistence of AF after pacemaker implan-
tations. No signiﬁcant differences were found in the baseline characteristics between the RAA
and LAS groups regardless of an AF history. During a 1-year follow-up period, in the SSS patients
without a history of AF, 19.0% (7/36) of the RAA group developed de novo AF, however, 5.9%
(1/17) of the LAS group developed de novo AF (p = 0.20). On the other hand, in the SSS patients
with a history of AF, 22.0% (6/27) of the RAA group developed persistent AF, but none of the
LAS group developed any persist
related to the LAS pacing.
Conclusions: LAS pacing is safe a
tent AF in SSS patients with dua
© 2011 Japanese College of Car
∗ Corresponding author. Tel.: +81 6 6879 3640; fax: +81 6 6879 3639.
E-mail address: hminami@medone.med.osaka-u.ac.jp (H. Minamiguch
0914-5087/$ — see front matter © 2011 Japanese College of Cardiology.
doi:10.1016/j.jjcc.2010.11.002ent AF (p = 0.049). There were no post-operative complications
nd feasible. LAS pacing may prevent the progression to persis-
l-chamber pacemakers.
diology. Published by Elsevier Ltd. All rights reserved.
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History of AF
(n=53)
SSS patients 
(n=95)
without
2 or 3 AVB
follow-upofyear1thanless History of AF (+)
(n=42)
SSS, sick sinus syndrome; AVB, atrioventricular block;
AF, atrial fibrillation; LAS, low atrial septum;                
RAA, right atrial appendage.
groupLAS
(-)
(n=17)
RAA group
(n=36)
groupLAS
(n=15)
RAA group 
(n=27)
Figure 1 This shows the allocation of the patients. Ninety-ﬁve
consecutive sick sinus syndrome (SSS) patients were analyzed.
Patients with SSS associated with acquired second- or third-
degree atrioventricular block (AVB) and those with less than
a 1-year of follow-up were excluded from this study. Forty-two
patients (44%) had a history of atrial ﬁbrillation (AF) at the time
of the pacemaker implantation. In the group without a history of
AF, low atrial septal (LAS) pacing was performed in 17 patients,
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ntroduction
trial ﬁbrillation (AF) is the most common cardiac rhythm
isturbance and contributes substantially to cardiac mor-
idity and mortality. It carries a considerable risk of
hromboembolisms and sustained AF, with an uncontrolled
entricular response rate, and can cause congestive heart
ailure with an increased risk of death [1]. AF is frequently
ncountered in pacemaker patients, most commonly in
hose with sick sinus syndrome (SSS) [2—4]. Atrial pacing was
eported to be effective for the prevention of AF because of
he suppression of premature atrial contractions that initi-
te reentry and predispose to AF [5—9]. Furthermore, atrial
eptal pacing, compared with right atrial appendage (RAA)
acing, shortens the atrial conduction time and reduces the
ispersion of the refractoriness [10,11]. However, whether
ow atrial septal (LAS) pacing can reduce the initiation
nd maintenance of AF clinically remains controversial. We
ought to compare standard RAA lead implantations with LAS
ead implantations for the prevention of AF in SSS patients
ith dual-chamber pacemakers, based on whether or not
hey had a history of AF.
ethods
tudy protocol
etween January 2002 and June 2007, 95 consecutive SSS
atients (average age 72± 9 years, 39 males) with standard
ndications for a dual chamber pacemaker were retrospec-
ively analyzed. The follow-up period was deﬁned as 1 year.
atients with SSS associated with acquired second- or third-
egree atrioventricular block and those with less than a
-year follow-up were excluded from this study. Forty-two
atients (44%) had a history of AF at the time of the pace-
aker implantation. In the group without a history of AF,
AS pacing was performed in 17 patients, and RAA pacing
n 36 patients. In the group with a history of AF, LAS pacing
as performed in 15 patients, and RAA pacing in 27 patients
Fig. 1). The implantable devices were an Intelis II DR (n = 3),
exus DR (n = 2) (Guidant Corp., St. Paul, MN, USA), Kappa
R (n = 13) (Medtronic Inc., Minneapolis, MN, USA), Afﬁnity
R (n = 7), Integrity DR (n = 9), and Identity DR (n = 61) (St
ude Medical, Sylmar, CA, USA). The atrial leads implanted
ere a ThinLine II EZ 438-35S (n = 5) (Guidant Corp.), Cap-
ure FIX 5068 (n = 13) (Medtronic Inc.), Tendril 1488T (n = 41)
nd Tendril 1688T (n = 36) (St Jude Medical). The tip to ring
pacing of all the atrial leads was 10mm. The lower rate
as set between 50 and 70 bpm (mean 59± 6 bpm), and the
rogrammed AV delay between 150ms and 300ms (mean
12± 40ms). The ventricular leads were all inserted in the
pex. The mode switch features were all programmed to
ccur for atrial rates of >225 bpm and the bipolar atrial
ensitivity was set to 0.5mV or at a 4:1 safety margin,
hichever yielded the more sensitive setting. The post-
entricular atrial blanking (PVAB) period was programmed
o be adapted on an individual basis after speciﬁc assess-
ent for the presence of a far-ﬁeld R-wave if the interval
rom the ventricular stimulus to the far-ﬁeld signal exceeded
he minimal programmed PVAB interval. Patients underwent
clinical assessment, standard 12-lead electrocardiogram
1
d
fnd right atrial appendage (RAA) pacing in 36. In the group with
history of AF, LAS pacing was performed in 15 patients, and
AA pacing in 27.
ECG), recording and interrogation of their pacemaker at
he pacemaker clinic.
ead implantation procedure
n active ﬁxation lead was placed into the RAA using the
tandard technique. The lead position was conﬁrmed via ﬂu-
roscopy (Fig. 2A and B). During the LAS lead implantation,
n atrial lead was introduced into the right atrium using
tandard techniques. With ﬂuoroscopy in the left anterior
blique (LAO) position, the lead was rotated toward the
nteratrial septum around the coronary sinus ostium using
LocatorTM (St Jude Medical) (Fig. 3A and B). We conﬁrmed
hat atrial pacing exhibited negative P waves in leads II, III,
nd aVf of the 12-lead ECG (Fig. 4).
eﬁnitions
history of AF was deﬁned as the occurrence of any of the
ollowing two circumstances:
1) Formerly documented AF already having been recorded
in a 12-lead ECG or Holter ECG.
2) The presence of both more than 1min of mode switching
and documented AF on the intracardiac electrograms
within 1 week after the pacemaker implantation.
De novo AF was deﬁned as the presence of both more than
min of mode switching and documented AF on the intracar-
iac electrograms 1 week after the pacemaker implantation.
Persistent AF was deﬁned as the occurrence of any of the
ollowing three circumstances [12]:
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RFigure 2 X ray showing the atrial lead implanted in the right
oblique (LAO) view.
(1) Two consecutive visits in which AF was present.
(2) At least 22 h of AF for at least 7 consecutive days,
detected by means of the diagnostic data stored in the
pacemaker.
(3) At least 22 h of AF per day for fewer than 7 consecutive
days if an interruption by electrical or pharmacologic
cardioversion occurred.
Evaluation
We evaluated the patients as follows:(1) The efﬁcacy of the prevention of AF during LAS pacing.
(a) The prevention of de novo AF in patients without a
history of AF.
(b) The prevention of the progression to persistent AF
in patients with a history of AF.
P
T
g
Figure 3 X ray showing the atrial lead implanted in the low atrial s
(LAO) view.al appendage. (A) Anteroposterior (AP) view. (B) Left anterior
2) The safety of LAS pacing: the post operative complica-
tions.
tatistical analysis
n independent-sample t-test and Pearson 2 test were
sed to compare the quantitative and categorical variables
etween groups, respectively. All continuous data were
xpressed as the mean± SD. A p < 0.05 was considered sta-
istically signiﬁcant.
esultsatients without a history of AF
here were no statistical differences regarding the age,
ender, history of hypertension or diabetes mellitus, B-type
eptum. (A) Anteroposterior (AP) view. (B) Left anterior oblique
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aigure 4 Twelve-lead electrocardiogram. The left side shows
he P waves in leads II, III, and aVf are inverted and negative
10ms to 100ms.
atriuretic peptide (BNP) level, or echocardiographic
arameters, including the ejection fraction or left atrium
iameters. The medical treatment during the follow-up
eriod was similar between the LAS and RAA groups
Table 1). At the time of the pacemaker implantations, the
trial and ventricular thresholds and P-wave and R-wave
ensing data were also similar between the LAS and RAA
roups. The AF SuppressionTM algorithm (St Jude Medical)
as not used in the SSS patients without a history of AF.
uring a 1-year follow-up period, the cumulative percent
d
t
n
(
Table 1 Baseline characteristics of the patients without a histor
LAS (n = 1
Age (years) 72± 10
Male gender, % (n) 47(8)
Hypertension, % (n) 71(12)
Diabetes mellitus, % (n) 18(3)
Structural heart disease, % (n) 12(2)
Hemodialysis, % (n) 6(1)
Complication of I degree AVB, % (n) 6(1)
Echocardiographic parameters
LVDd (mm) 46± 5
LVDs (mm) 27± 5
LAD (mm) 39± 6
EF (%) 72± 8
BNP (pg/ml) 279± 666
Medications
Sodium channel blocker, % (n) 6(1)
 Blocker, % (n) 0(0)
ACEI and/or ARB, % (n) 35(6)
Statin, % (n) 6(1)
LAS, low atrial septum; RAA, right atrial appendage; AVB, atrioventricul
left ventricular dimension; LAD, left atrial dimension; EF, ejection fract
enzyme inhibitors; ARB, angiotensin receptor blocker.al sinus rhythm and the right side low atrial septal (LAS) pacing.
ng low atrial septal pacing. The P wave width shortened from
f atrial paced beats (Cum%AP) was similar between the
AS and RAA groups (51% vs. 57%, respectively; p = 0.49),
owever the cumulative percent of ventricular paced beats
Cum%VP) was lower in the LAS group than in the RAA
roup (10% vs. 28%, respectively; p = 0.03) (Table 2). As
result, 19.0% (7/36) of the patients in the RAA groupeveloped de novo AF, but only 5.9% (1/17) of those in
he LAS group developed de novo AF. However, there was
o statistical difference between the two groups (p = 0.20)
Fig. 5).
y of atrial ﬁbrillation (AF).
7) RAA (n = 36) P
69± 13 0.39
39(14) 0.57
64(23) 0.23
17(6) 0.93
33(12) 0.10
3(1) 0.59
11(4) 0.54
48± 6 0.36
30± 7 0.19
36± 8 0.26
68± 11 0.24
136± 242 0.49
8(3) 0.69
11(4) 0.13
39(14) 0.63
19(7) 0.20
ar block; LVDd, diastolic left ventricular dimension; LVDs, systolic
ion; BNP, B-type natriuretic peptide; ACEI, angiotensin-converting
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Table 2 Pacemaker function during the implantation and follow-up.
SSS without a history of AF SSS with a history of AF
LAS (n = 17) RAA (n = 36) P LAS (n = 15) RAA (n = 27) P
Pacemaker implantation
Atrial threshold (V) 0.8± 0.6 0.7± 0.3 0.20 0.8± 0.5 0.8± 0.5 0.96
P-wave sensing (mV) 2.0± 1.3 2.4± 1.3 0.42 2.4± 0.7 2.1± 1.4 0.49
Ventricular threshold (V) 0.2± 0.1 0.3± 0.4 0.54 0.2± 0.1 0.2± 0.1 0.97
R-wave sensing (mV) 13.8± 6.5 14.7± 5.9 0.62 16.3± 6.7 15.2± 6.0 0.58
Follow-up
AFS on more than 3 months 0(0) 0(0) 1.0 40(6) 26(7) 0.34
Cumulative % atrial paced (%) 51± 25 57± 30 0.49 59± 25 59± 25 0.81
8± 3
tum;
m
l
p
o
(
P
D
dCumulative % ventricular paced (%) 10± 13 2
SSS, sick sinus syndrome; AF, atrial ﬁbrillation; LAS, low atrial sep
Patients with a history of AF
There were no statistical differences regarding the age, gen-
der, history of hypertension or diabetes mellitus, BNP level,
or echocardiographic parameters, including the ejection
fraction or left atrium diameters. The medical treatment
was similar between the LAS and RAA groups (Table 3). The
medical treatment shown in Table 3 consisted of only rou-
tine medications. The occurrence of atrial arrhythmias is
not included in that table. During the pacemaker implan-
tations, the atrial and ventricular thresholds and P-wave
and R-wave sensing data were also similar between the LAS
and RAA groups. During the follow-up period, the Cum%AP
and Cum%VP were similar between the LAS and RAA groups
(59% vs. 59%, p = 0.81; 32% vs. 37%, p = 0.68, respectively)
(Table 2). The utility of the AF SuppressionTM algorithm after
p
s
d
T
c
Figure 5 The development of atrial ﬁbrillation (AF) (follow-up peri
(SSS) patients without a history of AF, 19.0% (7/36) of the patients i
novo AF, but only 5.9% (1/17) of those in the low atrial septal (LAS
hand, in the SSS patients with a history of AF, 22.0% (6/27) of the p
the LAS group developed persistent AF (p = 0.049).1 0.03 32± 37 37± 38 0.68
RAA, right atrial appendage; AFS, atrial ﬁbrillation suppression.
ore than 3 months from the implantation was also simi-
ar (40% vs. 27%, p = 0.34). As a result, 22.0% (6/27) of the
atients in the RAA group developed persistent AF, but none
f those in the LAS group developed persistent AF (p = 0.049)
Fig. 5).
ost-operative complications
uring the follow-up period, there were no atrial lead
islodgements, perforations, pericarditis, or diaphragmatic
acing events noted. The atrial thresholds and P-wave
ensing issues did not change between data obtained imme-
iately after the implantation and at 1-year follow-up.
here were no known patient deaths related to pacemaker
omplications.
od; 9 months) is shown in this ﬁgure. In the sick sinus syndrome
n the right atrial appendage (RAA) pacing group developed de
) pacing group developed de novo AF (p = 0.20). On the other
atients in the RAA group developed persistent AF, but none in
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Table 3 Baseline characteristics of the patients with a history of atrial ﬁbrillation (AF).
LAS (n = 15) RAA (n = 27) P
Age (years) 73± 8 73± 7 0.90
Male gender, % (n) 53(8) 37(10) 0.31
Hypertension, % (n) 60(9) 59(22) 0.13
Diabetes mellitus, % (n) 20(3) 15(4) 0.67
Structural heart disease, % (n) 40(6) 37(10) 0.92
Hemodialysis, % (n) 13(2) 4(1) 0.26
Complication of I degree AVB, % (n) 7(1) 0(0) 0.17
Echocardiographic parameters
LVDd (mm) 46± 4 48± 6 0.42
LVDs (mm) 28± 5 30± 7 0.35
LAD (mm) 40± 4 42± 7 0.57
EF (%) 71± 10 67± 11 0.38
BNP (pg/ml) 452± 962 157± 239 0.25
Medications
Sodium channel blocker, % (n) 33(5) 19(5) 0.31
 Blocker, % (n) 20(3) 19(5) 0.95
ACEI and/or ARB, % (n) 20(3) 33(9) 0.32
Statin, % (n) 13(2) 19(5) 0.59
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LLAS, low atrial septum; RAA, right atrial appendage; AVB, atrioven
left ventricular dimension; LAD, left atrial dimension; EF, ejection
enzyme inhibitors; ARB, angiotensin receptor blocker.
iscussion
his observational study suggested that LAS pacing was
ffective for preventing the persistence of AF in patients
ith SSS undergoing dual-chamber pacemaker implanta-
ions, and the pacing thresholds and sensing data were
imilar to that of RAA pacing. In recent years, various types
f atrial pacing that might reduce the occurrence of AF
ave been studied. Several reports have suggested that
ite-speciﬁc atrial pacing, e.g. high atrial septal pacing,
hat is Bachmann’s bundle, low atrial septal, LA, or dual-
ite atrial pacing, might be more effective by virtue of
hortening the total interatrial activation times. Multi site
acing has generally positive results [13—16]. However, the
sual methods of bi-atrial stimulation require two leads: one
laced in the RA and another in the LA, using the coro-
ary sinus. The LA lead can be placed by inserting a lead
n the proximal coronary sinus. This approach has the dis-
dvantage of requiring an extra lead, which increases the
ost and difﬁculty of the implant procedure. Atrial septal
acing is a simple method, which may produce simultane-
us bi-atrial stimulation, using a single lead. Prior clinical
rials of atrial septal pacing have produced mixed results
15—27]. The study by Bailin of Bachmann’s bundle pacing
howed positive results with a longer survival-free rate of
F as compared with RAA pacing [24]. A study by Padeletti
t al. in 2001 showed the beneﬁt of septal pacing in 46
atients randomized to RAA pacing or septal pacing in the
revention of paroxysmal AF [25]. Pacing from the atrial
eptum was reported to shorten the atrial conduction time
nd improve the dispersion of the refractoriness [10]. As
hown in Fig. 4, the P wave width shortened with pacing
rom 110ms to 100ms. Consequently, atrial pacing was able
o inhibit the triggered premature atrial conducted beats
rom the pulmonary veins (PVs) due to a shorter conduc-
a
d
m
[ar block; LVDd, diastolic left ventricular dimension; LVDs, systolic
ion; BNP, B-type natriuretic peptide; ACEI, angiotensin-converting
ion time between the atrial pacing from the LAS and PVs,
s compared to the atrial pacing from the RAA. Moreover,
n improvement in the dispersion of the refractoriness may
odify the atrial substrate and inhibit the progression to
ersistent AF. However, a later, large multi-center study of
he combined effect of septal pacing and AT/AF tachycardia
acing prevention algorithms failed to show the beneﬁt of
trial septal pacing [26,27]. Sweeney et al. reported that
nnecessary ventricular pacing correlated with the persis-
ence of AF in patients with SSS [12], however the previous
tudies having a short AV delay and higher Cum%VP may
ave induced the onset of AF regardless of the region of the
trial leads. In this study, the AV interval was dependent
n the discretion of the physician, but ventricular sensing
ook precedence as often as possible. In the group with a
istory of AF, due to frequent mode switches from DDD to
DIR during AF, the atrial pacing sites were not affected by
he AV intervals, and the Cum%VP was similar between the
wo groups. However, the Cum%VP was lower for LAS pac-
ng than RAA pacing because of the shorter conduction time
rom the atrial pacing site to the ventricular sensing site in
hose without a history of AF. In the SSS patients with long
Q intervals, LAS pacing may be more effective when con-
idering the Cum%VP. Some patients with a history of AF had
high frequency of mode switches, but remained in sinus or
pacing rhythm. This suggests that LAS pacing may be more
ffective than RAA pacing in inhibiting the progression to
ersistent AF in patients with a large sized LA. On the other
and, Bachmann’s bundle pacing showed positive results,
owever, the atrial lead placement was much easier at the
AS using a LocatorTM than in Bachmann’s bundle region,
nd the ascending aorta is located behind Bachmann’s bun-
le anatomically, so implantations of the atrial screw-in lead
ay involve the risk of a perforation of the ascending aorta
28].
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The limitations of this study may include the following.
First, the follow-up periods were relatively short. Longer
term results are desirable. Second, the programmed AV
delays were dependent on the discretion of the physicians,
however, ventricular sensing was given precedence as often
as possible. Third, asymptomatic and unrecognized AF may
be included in the SSS patients without a history of AF
because asymptomatic and unrecognized AF was very com-
mon in those with SSS. The use of only the 12-lead ECG and
Holter ECG recordings before the pacemaker implantations
was insufﬁcient for detecting the AF episodes, so we deﬁned
the patients with a history of AF as those having more than
1min of mode switching within 1 week after the pacemaker
implantation as well as any documented AF in the 12-lead
ECG and Holter ECG recordings. Fourth, the allocation to
LAS and RAA pacing was not parallel. An allocation bias may
have affected the results, however, the SSS patients were
consecutive patients and there were no statistical differ-
ences in the patient background between the LAS and RAA
groups. We expect there would be the same results for the
safety and efﬁcacy of LAS pacing. Fifth, all right ventricular
(RV) leads were implanted in the RV apex. RV septal pac-
ing affects a different ventricular motion [29] than RV apex
pacing, and consequently may affect the development of
AF and progression to persistent AF. However, the Cum%Vp
was relatively low in the SSS patients, and we expect there
would be the same results regardless of the RV pacing site.
Sixth, this study had a small sample size and used an obser-
vational and non-randomized analysis. A large, prospective,
and multi-center trial may be required.
Conclusions
LAS pacing is safe and feasible. LAS pacing, compared to
traditional RAA pacing, may inhibit the maintenance of AF
in SSS patients with paroxysmal AF.
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